Showing 2391-2400 of 4063 results for "".
- Kala Pharmaceuticals Announces NDA for KPI-121 0.25% for Dry Eye Disease Has Been Accepted for Review by FDAhttps://modernod.com/news/kala-pharmaceuticals-announces-nda-for-kpi-121-0-25-for-dry-eye-disease-has-been-accepted-for-review-by-fda/2476240/Kala Pharmaceuticals announced that the new drug application (NDA) for KPI-121 0.25%, a product candidate for the temporary relief of signs and symptoms of dry eye disease utilizing a 2-week course of therapy, has been accepted for review by the FDA. The FDA has set a target action date under the
- Eyenovia Initiates Phase 3 MicroStat Program for Pharmacologic Mydriasis: Enrolls First Patient in MIST-1 Studyhttps://modernod.com/news/eyenovia-initiates-phase-3-microstat-program-for-pharmacologic-mydriasis-enrolls-first-patient-in-mist-1-study/2479648/Eyenovia announced that it has enrolled the first patient in the first of two phase 3 trials (MIST-1 and MIST-2) of the company’s MicroStat program for pharmacologic mydriasis. The studies will investigate the safety and efficacy of the company’s first-in-class fixed-combination p
- Warby Parker Eyewear Now Available to People Enrolled in UnitedHealthcare Medicare Advantage Planshttps://modernod.com/news/warby-parker-eyewear-now-available-to-people-enrolled-in-unitedhealthcare-medicare-advantage-plans/2479652/For the first time, Warby Parker is accepting Medicare insurance. The company’s designer prescription eyewear is available to approximately 2 million people enrolled in UnitedHealthcare Medicare Advantage plans, either online or at more than 80 Warby Parker stores nationwide, according to a
- Study: Diabetes Medication May Protect Against AMDhttps://modernod.com/news/study-diabetes-medication-may-protect-against-amd/2479722/Researchers from Taiwan have shown that people with type 2 diabetes who took a common diabetes medication, metformin, had a significantly lower rate of age-related macular degeneration (AMD). The study suggests that the anti-inflammatory and anti-oxidative effects
- Novartis: Two-Year Head-to-Head Data for Brolucizumab Reaffirm Superiority vs Aflibercept in Reducing Retinal Fluid in Patients With Wet AMDhttps://modernod.com/news/novartis-two-year-head-to-head-data-for-brolucizumab-reaffirm-superiority-vs-aflibercept-in-reducing-retinal-fluid-in-patients-with-wet-amd/2479727/Novartis announced additional brolucizumab phase 3 results from year 2 (96 weeks) that reaffirmed its positive year 1 (48 weeks) findings. Brolucizumab met its primary endpoint of noninferiority versus aflibercept in best corrected visual acuity (BCVA) and exhibited superiority in key retinal out
- New STAIRWAY Study Data Shows Potential for Extended Durability with Faricimab in Wet AMDhttps://modernod.com/news/new-stairway-study-data-shows-potential-for-extended-durability-with-faricimab-in-wet-amd/2479728/Genentech announced positive results from the phase 2 STAIRWAY study which explored the extended durability of faricimab (RG7716) in the treatment of wet age-related macular degeneration (AMD). At 52 weeks, faricimab patients dosed either every 16 weeks or every 12 weeks demonstrated sustained vi
- Statins, Fibrates Lower Diabetic Retinopathy Risks in Diabeteshttps://modernod.com/news/statins-fibrates-lower-diabetic-retinopathy-risks-in-diabetes/2479824/The use of lipid-lowering medication with fibrates, including fenofibrate (Lipidil, Abbott), and statins reduces not only the incidence of diabetic retinopathy in patients with type 2 diabetes but also the need for treatment in those who already have the condition, indicates a real-world J
- FDA Approves 12-Week Dosing for Eylea in Wet AMD Patientshttps://modernod.com/news/fda-approves-12-week-dosing-for-eylea-in-wet-amd-patients/2479932/Regeneron announced that the FDA has approved a supplemental Biologics License Application for Eylea (aflibercept) injection in patients with wet age-related macular degeneration (AMD). The application was based on second-year data from the phase 3 VIEW 1 and 2 trials in which patients with wet A
- Genentech Unveils New Clinical Data For the First Eye Implant for Wet AMDhttps://modernod.com/news/genentech-unveils-positive-phase-2-results-for-the-first-eye-implant-for-wet-amd/2479987/Genentech announced positive topline results from the phase 2 LADDER study evaluating the efficacy and safety of its investigational Port Delivery System (PDS) with ranibizumab in people with wet age-related macular degeneration (AMD). The small, refillable eye implant, which is slightly l
- New Acucela Data on the Effect of Emixustat Hydrochloride on Retinal Thickness in Diabetic Retinopathyhttps://modernod.com/news/new-acucela-data-on-the-effect-of-emixustat-hydrochloride-on-retinal-thickness-in-diabetic-retinopathy/2480075/Acucela announced new data on the effect of emixustat hydrochloride on retinal thickness in diabetic retinopathy (DR). The study (protocol 4429-203) is a randomized, placebo-controlled, phase 2 clinical trial exploring the effect of oral emixustat hydrochloride in a proliferative diabetic